OGI FY2025 EPS Forecast Reduced by Alliance Global Partners

Key Points

• Alliance Global Partners has reduced its forecast for Organigram's FY2025 earnings per share from $0.09 to $0.07, indicating a downward revision in expectations.
• Organigram's recent quarterly results reported an EPS of ($0.03), missing the consensus estimate of ($0.01) by $0.02, with revenues falling short of expectations at $50.49 million.
• Despite the downturn in earnings projections, significant changes in institutional investor positions suggest continued interest, with 34.63% of Organigram's stock held by such investors.

Organigram Global Inc. (NASDAQ:OGI - Free Report) - Analysts at Alliance Global Partners lowered their FY2025 earnings estimates for Organigram Global in a report released on Wednesday, August 13th. Alliance Global Partners analyst A. Grey now expects that the company will earn $0.07 per share for the year, down from their prior forecast of $0.09. The consensus estimate for Organigram Global's current full-year earnings is ($0.19) per share. Alliance Global Partners also issued estimates for Organigram Global's Q1 2026 earnings at ($0.02) EPS.

Organigram Global Price Performance

Shares of Organigram Global stock traded down $0.03 during midday trading on Friday, hitting $1.54. The company had a trading volume of 75,294 shares, compared to its average volume of 722,050. The business's 50 day simple moving average is $1.42 and its two-hundred day simple moving average is $1.27. The stock has a market cap of $205.74 million, a PE ratio of 30.71 and a beta of 1.45. Organigram Global has a 1-year low of $0.85 and a 1-year high of $2.08.

Organigram Global (NASDAQ:OGI - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.02). The company had revenue of $50.49 million for the quarter, compared to analyst estimates of $68.04 million. Organigram Global had a net margin of 2.86% and a negative return on equity of 8.49%.

Hedge Funds Weigh In On Organigram Global

A number of hedge funds and other institutional investors have recently made changes to their positions in OGI. Baader Bank Aktiengesellschaft bought a new position in shares of Organigram Global during the 2nd quarter worth about $338,000. Dimensional Fund Advisors LP boosted its stake in shares of Organigram Global by 13.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 359,739 shares of the company's stock valued at $579,000 after purchasing an additional 43,721 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in shares of Organigram Global by 140.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 69,753 shares of the company's stock valued at $94,000 after purchasing an additional 40,753 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of Organigram Global in the 2nd quarter valued at $54,000. Finally, Oxford Asset Management LLP acquired a new stake in shares of Organigram Global in the 4th quarter valued at $50,000. 34.63% of the stock is owned by institutional investors.

Organigram Global Company Profile

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.